Vertex Pharmaceuticals (VRTX) said Friday it received approval from the UK's Medicines and Healthcare products Regulatory Agency for Alyftrek to treat cystic fibrosis in patients six years and older with at least one F508del or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene.
Alyftrek is a triple combination cystic fibrosis transmembrane conductance regulator modulator treatment, the company added.
The US Food and Drug Administration approved Alyftrek in December 2024.
Price: 488.10, Change: +2.38, Percent Change: +0.49
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。